Takeda Pharmaceutical Ltd ADR (NY: TAK )
16.30 +0.08 (+0.49%) Streaming Delayed Price Updated: 12:25 PM EDT, Mar 24, 2023 Add to My Watchlist
All News about Takeda Pharmaceutical Ltd ADR
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
February 18, 2023
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...
Takeda Named Global Top Employer for Sixth Consecutive Year
January 16, 2023
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following